扩张型心肌病心力衰竭患者HLA-DQA1及-DQB1基因多态性研究

目的研究人类白细胞抗原(HLA)-DQA1,-DQB1基因多态性对扩张型心肌病(IDC)心力衰竭患者心功能的影响.探讨IDC发病的免疫学机制及遗传易感性.方法采用PCR-SSP方法对68例无血缘关系、长期居住在中国北方地区的汉族IDC患者和4个IDC家系成员及100名健康者进行HLA-DQA1,-DQB1基因分型;IDC组所有研究对象均接受超声心动图检测心脏射血分数(EF值)并据此进行分层EF值35%～50%者为亚组1,EF值15%～35%者为亚组2,＜15%者为亚组3.结果HLA-DQA1*0501基因和HLA-DQB1*0303基因频率在IDC组(分别为0.3889和0.1806)明显高于正常对照组(分别为0.0900和0.0364),OR值分别为5.20(95%CI3.60-8.50)和4.85(95%CI2.56-9.39).且该趋势随射血分数降低而愈趋明显,表现为HLA-DQA1*0501及HLA-DQB1*0303基因型在EF值＜15%的IDC患者中分布高于EF值≥15%者.相反,IDC组HLA-DQAl*0201基因(0.2000比0.0139)和HLA-DQB1*0502(0.0727比0.0139)、*0504(0.1091比0.0417)基因明显低于正常对照组(P＜0.05).IDC组中HLA-DQAI*0501基因型患者与IDC组中其他基因患者相比,临床心力衰竭症状较重,EF值明显降低(P＜0.01).HLA-DQB1各基因型间EF值未见统计学差异.HLA-DQA1,-DQB1基因与IDC家系连锁分析LOD值＜1.结论HLA-DQA1*0501和HLA-DQB1*0303与我国北方汉族IDC患者遗传易感性相关;而HLA-DQA1*0201和-DQB*0502、*0504则是IDC的保护基因.DQB1基因外显子第57位的丝氨酸对IDC具有保护性,其缺失或取代有可能造成IDC易患倾向.HLA-DQ基因多态性可作为IDC的遗传标记.     

HLA-DQ等位基因与哮喘相关性研究

目的探讨在中国汉族哮喘家系中,HLA-DQ基因与哮喘的相关性。方法对98例哮喘家系成员,用PCR-序列特异性引物(PCR-SSP)技术对HLA-DQA1和B1进行基因分型,并与正常对照进行比较。结果发现DQA1*0101和DQA1*0601等位基因频率在哮喘患者组(40.0%,45.0%)较正常对照组(16.4%,13.4%)显著升高(χ2=6.1860,P<0.05,RR=3.39;χ2=11.6090,P<0.01,RR=5.27);DQB1*0303和DQB1*0601等位基因频率在哮喘患者组(55.0%,47.5%)较正常对照组(13.7%,13.7%)显著升高(χ2=15.7400,P<0.01,RR=7.68;χ2=10.9300,P<0.01,RR=5.69)。同时发现HLA-DQB1*0201等位基因频率在对屋尘螨抗原特异性IgE反应哮喘家系成员(39.4%)较家系中非特应症者（12.0％）显著高频表达(t=2.3825,P<0.05)。结论HLA-DQA1*0101,*0601和DQB1*0303,*0601是哮喘遗传易感等位基因;HLA-DQB1*0201限定对屋尘螨抗原特异性IgE反应。     

中国HLA-DQ基因多态性与重症肌无力相关性的系统评价

目的运用循证医学系统评价我国人类白细胞抗原(HLA)-DQ基因多态性与重症肌无力(MG)之间的相关性。方法计算机检索Pubmed、Ovid、Embase、CBM、CNKI、万方数据库、VIP等,查找2016年6月前发表的关于我国HLA-DQ基因多态性与MG之间关联的文献。按Cochrane系统评价的方法,由两名研究者独立进行质量评价和资料提取,采用RevMan5.2软件进行Meta分析。结果共纳入15篇文献,样本量为2 364例,其中病例组(MG组)1 073例,健康对照组1 291例。Meta分析结果示:增加重症肌无力风险的HLA-DQ等位基因有:HLA-DQA1*0102[OR=1.43,95%CI(1.14,1.81)]、HLA-DQB1*0301[OR=1.62,95%CI(1.29,2.03)]、HLA-DQB1*0501[OR=1.53,95%CI(1.16,2.01)];降低重症肌无力风险的HLA-DQ等位基因有:HLA-DQA1*0201[OR=0.61,95%CI(0.45,0.83)]、HLA-DQB1*0601[OR=0.55,95%CI(0.44,0.69)]、HLA-DQB1*0602[OR=0.49,95%CI(0.38,0.62)]。结论中国人群,重症肌无力的易感基因HLA-DQA1*0102、HLA-DQB1*0301、HLA-DQB1*0501,而HLA-DQA1*0201、HLA-DQB1*0601、HLA-DQB1*0602为重症肌无力的保护基因。     

湖北食管癌HLA-DQB1的基因多态性

目的从基因水平探讨湖北地区汉族人食管癌HLA-DQB1等位基因的遗传易感性.方法运用序列特异性引物聚合酶链反应技术,检测无亲缘关系湖北汉族健康人136例、食管癌组42例患者的HLA-DQB1等位基因.SAS system统计软件数据处理.结果湖北汉族人食管癌患者与正常人比较,HLA-DQB1*0301基因频率显著增高(0.2976vs0.1875),P=0.046,OR=1.835,病因分数=0.1354);两组间HLA-DQB1其余各等位基因分布频率的比较,HLA-DQB1*0201(0.0833 vs 0.1016),*0301(0.2976 vs 0.1875),*0302(0.0595 vs 0859),*0303(0.2381 vs 0.1875),*0304(0.0000 vs 0.0039),*0401(0.0714 vs 0.0469),*0402(0.0119 vs 0.0156),*0501(0.0357 vs 0.0703),*0502(0.0595 vs 0.0664),*0503(0.0119 vs 0.0195),*0504(0.0000 vs 0.0039),*0601(0.0595 vs 0.0781),*0602(0.0476 vs 0.0742),*0603(0.0000 vs 0.0078),*0604(0.0238 vs 0.0508),差异均无显著性.结论 HLA-DQB1*0301等位基因与湖北汉族人食管癌正关联,为其易感基因.林军,邓长生,孙洁,周燕,熊平,汪亚平.湖北食管癌HLA-DQB1的基因多态性.世界华人消化杂志,2000;8(9):965-968     

DQB1等位基因多态性与乙肝后肝硬化的遗传易感性研究

目的研究HLA-DQB1等位基因多态性与肝硬化的遗传易感性,为寻找肝硬化的易感基因或抗病基因提供线索.方法应用PCR-SSP技术检测106例湖北汉人乙肝后肝硬化患者和108例正常人HLA-DQB1等位基因,并结合临床资料进行比较分析.结果肝硬化组DQB1*0501等位基因频率明显升高(24.52%vs 11.11%,RR=2.6,P＜0.01),DQB1*0602等位基因频率明显下降(4.7%vs 12.03%,RR=0.3618,P＜0.05),其他等位基因频率在两组之间无显著性差异.提示DQB1*0501等位基因与湖北地区汉人乙肝后肝硬化关联,DQB1*0602等位基因则呈负关联.结论DQB1*0501等位基因可能是湖北地区汉族人乙肝后肝硬化的易感基因,DQB1*0602则为抵抗基因.     

HLA-DQB1*03基因与宫颈上皮内瘤样病变及宫颈癌的相关性研究

采用酚-氯仿-异戊醇法从宫颈上皮内瘤样病变(CIN)、宫颈癌患者及正常对照者的外周静脉血提取DNA,采取序列特异性引物的聚合酶链式反应法分离人白细扁抗原(HLA)-DQB1*03基因各亚型.发现DQB1*0301、0302、0303亚型的频率在CIN、宫颈癌组较正常组明显增高;在CIN组和宫颈癌组内,DQB1*0301、0303亚型的频率较高.认为HLA-DQB1*03基因亚型与CIN及宫颈癌的发生有关.     

1型糖尿病与HLA-DQB1基因及自身抗体相关性研究

采用基因分型技术,确定32例1型糖尿病患者及23例正常对照的HLA-DQB1等位基因.用酶联免疫吸附法测定血清中谷氨酸脱羧酶抗体(GADA)、胰岛细胞抗体(ICA)及胰岛素自身抗体(IAA).结果在1型患者中,DQB1*0201、*0303、*0604等位基因频率显著高于对照(P＜0.05),DQB1*0301则低于对照(P＜0.05),其余DQB1等无显著性差异.等位基因为DQB1*0201的患者中GADA阳性率显著高于阴性率.结论在中国汉族人群中,DQB1*0201、*0303、*0604是1型糖尿病易感性等位基因,DQB1*0301是1型糖尿病保护性等位基因.DQB1*0201可能对GADA的产生起允许作用.     

Curative effects of interferon-α and HLA-DRB1 -DQA1 and -DQB1 alleles in chronic viral hepatitis B

AIM: To investigate the association between curative effects of interferon-α and partial human leucocyte antigen (HLA)Ⅱ alleles in chronic viral hepatitis B.METHODS: Sixty patients with chronic viral hepatitis B in Shanghai were treated with a standard course of treatment with interferon-α for 6 mo. HLA-DRB1, -DQA1, and -DQB1 alleles were detected by polymerase chain reaction-sequence specific primer (PCR-SSP) method. RESULTS: Frequencies of HLA-DRB1*04(P＜0.025) and HLA-DQA1*0303 (P＜0.01) in non-responders were significantly higher than those in partial and complete responders. Frequencies of HLA-DQAI*0505(P＜0.025) and HLA-DQB1*0301(P＜0.005) in partial and complete responders were significantly higher than those in non-responders.CONCLUSION: Non-response to interferon-α therapy is positively correlated with HLA-DRB1*04 and HLA-DQA1*0303, and negatively correlated with HLA-DQA1*0505 and -DQB1*0301 in patient with chronic viral hepatitis B.HLA Ⅱ genes of the identification alleles provide a method for evaluating outcome of interferon-α treatment.     

肿瘤坏死因子-β基因多态性与特发性扩张性心肌病的相关性分析

目的 探讨肿瘤坏死因子(TNF)-β基因型的多态性与特发性扩张性心肌病(IDC)的相关性.方法 在吉林大学第一临床医院,选择86例IDC患者为IDC组、95例体检健康者为对照组,用ELlSA法检测血清TNF-β蛋白水平,采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析法检测TNF-β基因多态性变化.结果 IDC组TNF-β蛋白水平[(1.876±1.013)μg/L]高于对照组[(1.018±0.645)μg/L],组间比较差异有统计学意义(t=2.67,P<0.01);TNFμ*2等位基斟频率[63.4%(109/172)1高于对照组比[47.9%(91/190)],组间比较差异有统计学意义(x2=6.78,P<0.05),其比值比(伽)值为1.88.结论 TNFμ*2等位基因的多态性与IDC的易感性有关,可能是IDC的易感基因之一.     

人类白细胞抗原-DQA1*0301等位基因与腔隙性脑梗死的相关性研究

目的 针对腔隙性脑梗死多基因致病的特点,进行人类白细胞抗原(HLA)-DQA1等位基因分型,分析腔隙性脑梗死的遗传易感性。方法采用聚合酶链反应-序列特异性引物(PCR-SSP)联合技术对62例腔隙性脑梗死患及64名正常对照组进行HLA-DQA1等位基因的基因分型。结果 HLA-DQA1*0301基因频率在腔隙性脑梗死组明显高于正常对照组,原发性高血压阳性家族史的患组明显高于具有阴性家族史的患组,而DQA1*0103基因频率在正常对照组却明显增高。结论 8LA-DQA1*0301基因与腔隙性脑梗死的遗传易感性相关,与具有原发性高血压阳性家族史患的腔隙性脑梗死的发病相关;HLA-DQA1*0103基因可能是腔隙性脑梗死的保护性基因。     

Canada in the face of the 2009 H1N1 pandemic

Please cite this paper as: Moghadas et al. (2011) Canada in the face of the 2009 H1N1 pandemic. Influenza and Other Respiratory Viruses 5(2), 83–88. Background Initial public health responses to the 2009 influenza H1N1 pandemic were based on difficult decisions in the face of substantial uncertainty. Policy effectiveness depends critically on such decisions, and future planning for maximum protection of community health requires understanding of the impact of public health responses in observed scenarios. Objectives In alignment with the objectives of the Pandemic Influenza Outbreak Research Modelling Team (Pan‐InfORM) and the Centre for Disease Modelling (CDM), a focused workshop was organized to: (i) evaluate Canada's response to the spring and autumn waves of the novel H1N1 pandemic; (ii) learn lessons from public health responses, and identify challenges that await public health planners and decision‐makers; and (iii) understand how best to integrate resources to overcome these challenges. Main outcome measures We report on key presentations and discussions that took place to achieve the objectives of the workshop. Conclusions Future emerging infectious diseases are likely to bring far greater challenges than those imposed by the 2009 H1N1 pandemic. Canada must address these challenges and enhance its capacity for emergency responses by integrating modelling, surveillance, planning, and decision‐making.     

Cytochrome 1A1 and 1B1 gene diversity in the Zanzibar islands

Amodiaquine (AQ) is a 4‐aminoquinoline widely used in the treatment of malaria as part of the artemisinin combination therapy (ACT). AQ is metabolised towards its main metabolite desethylamodiaquine mainly by cytochrome P450 2C8 (CYP2C8). CYP1A1 and CYP1B1 play a minor role in the metabolism but they seem to be significantly involved in the formation of the short‐lived quinine‐imine. To complete the genetic variation picture of the main genes involved in AQ metabolism in the Zanzibar population, previously characterised for CYP2C8, we analysed in this study CYP1A1 and CYP1B1 main genetic polymorphisms. The results obtained show a low frequency of the CYP1A1*2B/C allele (2.4%) and a high frequency of CYP1B1*6 (approximately 42%) followed by CYP1B1*2 (approximately 27%) in Zanzibar islands. Genotype data for CYP1A1 and CYP1B1 show a low incidence of fast metabolisers, revealing a relatively safe genetic background in Zanzibar’s population regarding the appearance of adverse effects.     

Functions of the VEGF receptor-1 (FLT-1) in the vasculature

Vascular endothelial growth factor (VEGF) is a major inducer of angiogenesis and vasculogenesis. Two distinct receptors for VEGF, the tyrosine kinase receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), have been identified. Transfection studies could demonstrate biological activities for the Flk-1/KDR-, but not for the Flt-1-receptor, which led to the hypothesis that Flt-1 is a decoy receptor for VEGF. However, Flt-1 is biologically active in non-endothelial cells, namely monocytes, which exclusively express this receptor. In addition, the Flt-1 ligand placenta growth factor (PlGF), which is unable to bind and activate Flk-1/KDR, elicits activities in both monocytes and endothelial cells. The implications of Flt-1 mediated monocyte transmigration through endothelial monolayers and induction of the procoagulant tissue factor on monocytes for the field of vascular medicine are discussed.